Operose Advisors LLC Invests $543,000 in ImmunityBio, Inc. $IBRX

Operose Advisors LLC acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 62,057 shares of the company’s stock, valued at approximately $543,000.

A number of other institutional investors also recently bought and sold shares of the stock. WealthPlan Investment Management LLC acquired a new position in ImmunityBio during the 4th quarter valued at approximately $27,000. Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio during the second quarter worth $27,000. Kovack Advisors Inc. purchased a new stake in shares of ImmunityBio during the fourth quarter valued at $27,000. Empowered Funds LLC purchased a new stake in shares of ImmunityBio during the fourth quarter valued at $28,000. Finally, Markowski Investments acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $29,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ImmunityBio

In related news, Director Barry J. Simon sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the completion of the sale, the director owned 2,802,788 shares of the company’s stock, valued at approximately $22,085,969.44. The trade was a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director owned 125,386 shares of the company’s stock, valued at $1,191,167. This represents a 51.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 412,410 shares of company stock valued at $3,753,442 in the last three months. 66.10% of the stock is currently owned by company insiders.

ImmunityBio Trading Down 1.3%

ImmunityBio stock opened at $8.08 on Friday. ImmunityBio, Inc. has a 12 month low of $1.95 and a 12 month high of $12.43. The stock’s 50 day simple moving average is $7.90 and its two-hundred day simple moving average is $7.88. The firm has a market cap of $8.56 billion, a PE ratio of -8.33 and a beta of 0.04.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. On average, equities research analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current year.

Wall Street Analysts Forecast Growth

IBRX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research note on Friday, July 10th. BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and an average target price of $14.20.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.